Experimental stroke drug takes first step in human safety trial

NCT ID NCT05547438

Terminated Disease control Sponsor: NeuroTrauma Sciences, LLC Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This trial tests the safety of a single intravenous dose of an experimental drug called NTS-104 tris in healthy adults aged 18 to 65. The drug is being developed as a potential treatment for acute ischemic stroke. Researchers will monitor participants for side effects and measure how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called NTS-104 tris
What this could lead to: If safe, this drug could be tested in people who have had a stroke, potentially helping to limit brain damage.
What could go wrong: This is a very early, small safety study in healthy people, not stroke patients. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Show contact details

Locations

Parexel International EPCU Baltimore 7th floor

Baltimore, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.